A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
Clinical trial NCT06691113 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06691113
- Sponsor
- Sanofi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-16
- Primary completion
- 2026-03-31
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.